2020
Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer
Kim VM, Pan X, Soares KC, Azad NS, Ahuja N, Gamper CJ, Blair AB, Muth S, Ding D, Ladle BH, Zheng L. Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight 2020, 5: e136368. PMID: 32376802, PMCID: PMC7253020, DOI: 10.1172/jci.insight.136368.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerDNA methyltransferase inhibitorAntitumor efficacyAntigen-specific antitumor immune responsesAntitumor T-cell responsesCancer testis antigen expressionAntitumor immune responseT cell responsesAntitumor immunityCancer vaccinesSurvival outcomesCombination therapyAntigen expressionImmune responseMurine modelCTA expressionCell responsesNeoantigensImproved efficacyTumor cellsVaccineEfficacyGVAXMethyltransferase inhibitor
2008
Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers?
Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers? Annals Of Surgical Oncology 2008, 15: 2388. PMID: 18622647, PMCID: PMC3072702, DOI: 10.1245/s10434-008-0015-y.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerLeft-sided colon cancerProportional hazards regression analysisHazards regression analysisColon cancerMedian survivalCox proportional hazards regression analysisLongitudinal population-based databaseLong-term survival outcomesEnd Results Program databaseInvasive colon adenocarcinomaRight-sided cancersOverall median survivalLeft-sided cancersYear of diagnosisPopulation-based databaseRetrospective survival analysisSubset of subjectsRegression analysisSEER databaseSurgical resectionLymph nodesWorse prognosisSurvival outcomesTumor size